Last updated: September 6, 2026
Berdazimer sodium is the active ingredient in Zelsuvmi, a topical prescription treatment for molluscum contagiosum. The U.S. Food and Drug Administration approved Zelsuvmi in December 2023 for patients aged 1 year and older, and Journey Medical began commercial launch in early 2024. The drug entered a market with no FDA-approved prescription treatment before its approval, but its revenue potential is constrained by the self-limited nature of molluscum, pediatric prescribing dynamics, reimbursement uncertainty, and competition from off-label therapies.
Journey Medical owns the commercial rights through its relationship with Fortress Biotech. Berdazimer sodium has a differentiated mechanism, a non-systemic topical formulation, and an FDA-approved pediatric indication. Its commercial performance depends on physician adoption, payer coverage, pharmacy access, and the company’s ability to convert families from watchful waiting and office-based treatments.
What is berdazimer sodium and how does Zelsuvmi work?
Berdazimer sodium is a nitric oxide-releasing topical drug. Zelsuvmi is supplied as a two-part topical gel that is mixed before application. The active drug is applied once daily to molluscum lesions for up to 12 weeks.
The FDA-approved indication is treatment of molluscum contagiosum in adults and pediatric patients aged 1 year and older. Molluscum is a viral skin infection caused by a poxvirus. It is common in children and often resolves without treatment, although lesions can persist, spread, become inflamed, or create social and quality-of-life concerns.
The label instructs patients or caregivers to apply the product once daily to each lesion, avoiding the eyes and mouth. Common adverse reactions include application-site pain, erythema, exfoliation, and dermatitis. The topical route limits systemic exposure, which supports pediatric use, although local tolerability can affect treatment persistence and physician prescribing. (U.S. Food and Drug Administration, 2023)
When did berdazimer sodium receive FDA approval?
The FDA approved Zelsuvmi on December 14, 2023. The approval was based primarily on two Phase 3 studies, B-SIMPLE4 and B-SIMPLE2, evaluating complete lesion clearance after 12 weeks of treatment.
| Milestone |
Date or status |
| Active ingredient |
Berdazimer sodium |
| Product |
Zelsuvmi |
| Sponsor at approval |
Ligand Pharmaceuticals and Journey Medical-related development entities |
| FDA approval |
December 14, 2023 |
| Indication |
Molluscum contagiosum |
| Minimum approved age |
1 year |
| Dosage form |
Topical gel |
| Treatment schedule |
Once daily for up to 12 weeks |
| Commercial launch |
Early 2024 |
| Regulatory designation |
FDA-approved prescription drug |
Zelsuvmi was the first FDA-approved treatment specifically indicated for molluscum contagiosum. Before approval, treatment commonly involved observation, cryotherapy, curettage, cantharidin, topical retinoids, or other off-label approaches. The FDA approval gives Zelsuvmi a formal labeling advantage over these alternatives, but it does not guarantee broad insurance coverage.
How large is the commercial market for berdazimer sodium?
The addressable market is clinically large but commercially fragmented. Molluscum is common in children, yet many cases resolve spontaneously. That creates a gap between epidemiologic prevalence and the number of patients likely to receive prescription therapy.
Market demand is concentrated in several groups:
- Children with numerous or persistent lesions.
- Patients with lesions on visible areas of the body.
- Families seeking treatment before school, sports, camps, or social events.
- Patients with atopic dermatitis, where molluscum may spread more extensively.
- Patients whose lesions are painful, inflamed, or repeatedly traumatized.
- Families seeking an at-home alternative to office procedures.
Zelsuvmi competes against three broad treatment categories:
| Treatment category |
Examples |
Commercial effect on Zelsuvmi |
| Watchful waiting |
Observation until spontaneous resolution |
Reduces treatment conversion |
| Office procedures |
Cryotherapy, curettage, cantharidin |
Competes on speed and physician familiarity |
| Off-label topical treatment |
Retinoids and other compounded or prescribed agents |
Can be cheaper or easier to access |
| FDA-approved prescription therapy |
Zelsuvmi |
Gains labeling and evidence advantages |
The product’s commercial ceiling is likely below the total number of molluscum cases because many patients do not seek treatment, many clinicians continue to observe lesions, and some families prefer office-based removal.
What is the financial trajectory for Journey Medical and Zelsuvmi?
Zelsuvmi entered the market as an early-stage commercial product rather than a mature revenue asset. Its initial financial trajectory is likely to follow four phases:
- Launch investment. Journey Medical incurs sales, marketing, medical education, distribution, and market-access costs before prescription volume reaches scale.
- Prescription conversion. Revenue depends on dermatologist and pediatrician adoption, patient starts, pharmacy fulfillment, and completion of treatment.
- Payer and pricing adjustment. Gross-to-net deductions may increase as the company expands copay assistance, rebates, and access programs.
- Operating leverage. A successful product can generate margin improvement because topical manufacturing costs are generally lower than selling expenses, but profitability depends on sales volume and promotional intensity.
Journey Medical’s public filings provide consolidated company financial results, but Zelsuvmi performance should be separated from the company’s established dermatology products when assessing the asset. Public reporting may not provide a full product-level breakdown in every reporting period. That limits precise calculation of standalone Zelsuvmi revenue, gross margin, and contribution profit from publicly available filings. (Fortress Biotech, 2024)
The main financial variables are:
- Net revenue per prescription after rebates and patient support.
- New prescription volume.
- Refill or repeat-fill behavior during the 12-week treatment period.
- Product discontinuation caused by local irritation.
- Commercial payer coverage.
- Physician sampling and patient assistance costs.
- Sales force productivity.
- Manufacturing scale and inventory write-offs.
- Promotional competition from cantharidin and office procedures.
Because molluscum is often managed without treatment, the company must create demand rather than rely only on diagnosis volume. The drug’s commercial performance therefore depends on patient and caregiver willingness to pay for treatment, not only on disease prevalence.
What patents protect berdazimer sodium and Zelsuvmi?
The Zelsuvmi intellectual-property position is expected to include patents directed to the active compound, nitric oxide-releasing chemistry, topical formulations, and methods of treating molluscum contagiosum. The relevant protection can extend beyond a basic composition claim if issued patents cover:
- Berdazimer sodium and related nitric oxide donor structures.
- Stabilized topical gel systems.
- Two-component or mixed formulations.
- Specified concentration ranges.
- Manufacturing and storage methods.
- Treatment of molluscum with topical berdazimer.
- Pediatric dosing and administration methods.
The practical strength of the estate depends on claim scope, patent-term adjustment, expiration dates, Orange Book listing, and the ability to enforce claims against an abbreviated new drug application, or ANDA, applicant.
Publicly available product-label and company materials do not establish a complete, verified list of every issued patent, patent family, terminal disclaimer, patent-term extension, or Orange Book listing. A definitive freedom-to-operate or generic-entry analysis cannot be based only on the FDA label and corporate disclosures.
What formulations are protected by the berdazimer sodium estate?
The commercial formulation is a topical gel requiring combination of components before use. Formulation protection may be commercially important because a generic applicant could attempt to copy the active ingredient while using a different vehicle, packaging system, concentration, or mixing process.
Formulation claims are strongest when they capture a necessary feature of the approved product and cannot be easily designed around. They are weaker when alternative excipients, packaging configurations, or manufacturing processes can achieve similar stability and delivery.
The two-part presentation creates potential manufacturing and packaging barriers, but those barriers are not equivalent to regulatory exclusivity. An ANDA applicant may challenge formulation patents or develop a non-infringing formulation that remains pharmaceutically equivalent.
What is the Orange Book status and generic-entry risk for Zelsuvmi?
Zelsuvmi is an FDA-approved prescription drug, so Orange Book listing and patent certification issues are relevant to future generic competition. The main pathways are:
- A Paragraph III certification agreeing to wait until listed patent expiration.
- A Paragraph IV certification asserting that listed patents are invalid, unenforceable, or not infringed.
- A section viii statement carving out a patented method of use.
- A 505(b)(2) application for a modified formulation or indication.
A Paragraph IV filing could trigger patent litigation within 45 days of notice and potentially impose a 30-month stay of approval under the Hatch-Waxman framework. The commercial effect would depend on the patents asserted, the litigation outcome, pediatric exclusivity, and whether the generic applicant obtains tentative or final approval.
No widely reported public Paragraph IV litigation or generic launch involving Zelsuvmi had been established in the available public record through the early commercial period. That status can change as the product accumulates sales and attracts ANDA investment.
When does berdazimer sodium lose exclusivity?
FDA approval does not create a single, publicly stated “loss of exclusivity” date for Zelsuvmi. Market exclusivity depends on several separate rights:
- Patent expiration dates.
- Five-year new chemical entity exclusivity, if granted.
- Three-year clinical-investigation exclusivity for a new indication or formulation, where applicable.
- Six-month pediatric exclusivity, if earned.
- Orange Book-listed patents and litigation outcomes.
- Potential regulatory exclusivity for an orphan or other special designation, if applicable.
The product’s likely generic-entry window cannot be determined accurately without a verified Orange Book patent list and the complete patent-family record. Generic competition could arrive after applicable exclusivity expires, after successful Paragraph IV litigation, or through a competing regulatory pathway that avoids relevant claims.
Which companies compete with berdazimer sodium?
Zelsuvmi competes with established dermatology practices more than with a single direct branded rival.
Office-based competitors
Dermatologists may use cryotherapy, curettage, or cantharidin. These treatments can produce faster lesion removal but require an office visit and may cause pain, pigment changes, or procedural discomfort. Zelsuvmi’s home-use model is its main differentiation.
Off-label topical competitors
Topical retinoids and compounded agents can be prescribed in individual cases. These products generally lack Zelsuvmi’s FDA-approved molluscum indication, but may have lower acquisition costs or familiar reimbursement pathways.
Potential branded competitors
The principal future competitive risk is another topical or immune-directed treatment that offers faster clearance, lower irritation, easier application, or better payer coverage. A direct competitor would be most damaging if it achieved similar efficacy with fewer applications or a lower net price.
What licensing deals support berdazimer sodium commercialization?
Berdazimer sodium development involved commercial and licensing relationships associated with Journey Medical, Fortress Biotech, and Ligand Pharmaceuticals. These relationships can affect economics through royalties, milestone payments, manufacturing rights, and territory restrictions.
For investors, the key questions are:
- Which entity records product revenue?
- What royalty or milestone obligations reduce gross profit?
- Does the commercial partner control pricing and promotion?
- Are rights limited to the United States or extend internationally?
- Is the product dependent on a third-party manufacturer?
- Do supply agreements create minimum purchase or termination obligations?
The commercial value of Zelsuvmi is therefore lower than gross sales if royalties, rebates, patient assistance, distribution fees, and sales expenses are material.
What generic launch scenarios exist for Zelsuvmi?
Early challenge scenario
An ANDA applicant files a Paragraph IV certification before meaningful Zelsuvmi revenue develops. Litigation creates legal expense and uncertainty but may not materially disrupt the originator if the product remains commercially small.
Delayed generic scenario
Zelsuvmi builds a durable prescriber base and the patent estate delays generic approval until later in the product life cycle. This scenario gives Journey Medical more time to recover launch costs and expand the indication’s treatment rate.
Formulation design-around scenario
A competitor develops a therapeutically equivalent topical product using a different gel, mixing system, or concentration. This could reduce the value of formulation patents while preserving the importance of active-ingredient and method-of-use claims.
Commercial underperformance scenario
The product remains FDA-approved but adoption is limited by spontaneous resolution, local irritation, reimbursement restrictions, or caregiver reluctance to use a 12-week treatment. In that case, patent protection may have limited financial value because revenue does not reach a level that attracts rapid generic entry.
How strong is the berdazimer sodium patent estate?
The estate has commercial strengths because it can potentially combine active-ingredient, formulation, manufacturing, and method-of-use claims. Its weaknesses are typical of a first-in-class topical product:
- The disease is often self-limited.
- Alternative procedures are available.
- Formulation claims may be design-around targets.
- Method-of-use claims can be narrower than composition claims.
- The economic incentive for generic entry depends on prescription volume.
- Public confirmation of all listed patents and expiration dates is essential before a definitive litigation forecast.
The strongest protection would come from enforceable composition claims that cover the active ingredient and remain valid through the period when the product achieves meaningful sales. Formulation-only protection would generally create a narrower barrier.
Key Takeaways
- Berdazimer sodium is the active ingredient in Zelsuvmi, the first FDA-approved prescription treatment specifically indicated for molluscum contagiosum.
- The product launched in the United States in early 2024 after FDA approval in December 2023.
- Commercial demand is limited by spontaneous resolution, watchful waiting, office procedures, and off-label topical treatments.
- The core commercial advantage is at-home treatment with FDA-approved pediatric labeling.
- Financial performance depends more on prescription conversion, payer access, and net pricing than on disease prevalence alone.
- Product-level revenue and profitability should be distinguished from Journey Medical’s consolidated financial statements.
- Patent protection may include active-ingredient, formulation, manufacturing, and method-of-use claims, but a complete Orange Book and patent-expiration analysis requires verified patent-family data.
- No established public generic launch or major Paragraph IV litigation was identified in the early commercial period covered here.
- The principal investment risk is limited commercial penetration before a generic or competing treatment becomes viable.
FAQs
Is berdazimer sodium a biologic or a small-molecule drug?
Berdazimer sodium is a chemically synthesized topical small-molecule drug, not a biologic. Biosimilar competition is therefore not the relevant regulatory risk; ANDA-based generic competition is.
Is Zelsuvmi covered by insurance?
Coverage varies by payer and plan. The FDA approval supports formulary consideration, but coverage, prior authorization, copay requirements, and patient assistance terms determine the effective price paid by families.
Can a generic copy the Zelsuvmi gel?
A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable FDA standard. It may challenge listed patents or attempt a formulation that avoids particular formulation claims.
Does Zelsuvmi have pediatric exclusivity?
Pediatric exclusivity depends on completion of an FDA-requested pediatric study and issuance of the corresponding FDA exclusivity determination. It should not be assumed solely from the product’s pediatric indication.
What is the main commercial threat to berdazimer sodium?
The main near-term threat is not necessarily a generic. It is limited treatment adoption caused by watchful waiting, office-based procedures, caregiver reluctance, local tolerability, and inadequate reimbursement.
References
-
U.S. Food and Drug Administration. (2023, December 14). FDA approves first treatment for molluscum contagiosum. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-molluscum-contagiosum
-
U.S. Food and Drug Administration. (2023). Zelsuvmi (berdazimer) topical gel prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215064s000lbl.pdf
-
Fortress Biotech, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar/browse/?CIK=1429260
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (n.d.). Small business assistance: Frequently asked questions on the patent and exclusivity information in the Orange Book. https://www.fda.gov/drugs/development-resources/patent-and-exclusivity-information-drug-products-questions-and-answers
